Panacos Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
PANC Panacos Pharmaceuticals Inc
DPLS Darkpulse Inc
CAT Caterpillar Inc
AMT American Tower Corp
SUI Sun Communities Inc
XTNT Xtant Medical Holdings Inc
BAC Bank of America Corp
VST Vistra Corp
AVOA Avoca LLC
LHRP Lifehouse Retirement Properties Inc
Go

Health Care : Biotechnology |
Company profile

Panacos Pharmaceuticals, Inc. (Panacos) is a development-stage biotechnology company that seeks to develop next generation anti-infective products through the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The Company's lead product candidate, bevirimat, is an oral HIV drug candidate in Phase II clinical testing. Panacos has dosed over 485 patients and subjects with bevirimat and have seen a good safety and tolerability profile with no indication of a relationship between adverse events and drug levels. The Company has exclusive rights from University of North Carolina at Chapel Hill (UNC) to the United States patent claiming the chemical entity bevirimat. Panacos has an exclusive worldwide license with UNC for all indications.

Closing Price
$0.002
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.002
Day's Low
0.002
Volume
(Light)
Volume:
5

10-day average volume:
21,454
5

Display:

Providers:

UpdateCancel
6 providers

No news found.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.